Effect of NFE2L2 genetic polymorphism on the association between oral estrogen therapy and the risk of venous thromboembolism in postmenopausal women

Clinical Pharmacology and Therapeutics

Volumn 89, Issue 1, 2011, Pages 60-64

  Bouligand, J ^a,b   Cabaret, O ^a   Canonico, M ^c   Verstuyft, C ^a   Dubert, L ^a   Becquemont, L ^a   Guiochon Mantel, A ^a,b   Scarabin, P Y ^c  

^a UNIVERSITÉ PARIS SACLAY   (France)

^b INSERM   (France)

^c CENTRE FOR RESEARCH IN EPIDEMIOLOGY AND POPULATION HEALTH   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ESTRADIOL; TRANSCRIPTION FACTOR NRF2; ESTROGEN; NFE2L2 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; ESTROGEN THERAPY; FEMALE; GENETIC POLYMORPHISM; GENETIC RISK; GENOTYPE; HUMAN; LUNG EMBOLISM; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; WILD TYPE; CASE CONTROL STUDY; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG DETOXIFICATION; GENETIC ASSOCIATION; GENETICS; INTRADERMAL DRUG ADMINISTRATION; MIDDLE AGED; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; POSTMENOPAUSE; RISK; RISK FACTOR; VEIN THROMBOSIS; VENOUS THROMBOEMBOLISM;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, ORAL; AGED; CASE-CONTROL STUDIES; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; GENETIC ASSOCIATION STUDIES; HUMANS; METABOLIC DETOXICATION, PHASE II; MIDDLE AGED; NF-E2-RELATED FACTOR 2; ODDS RATIO; POLYMORPHISM, SINGLE NUCLEOTIDE; POSTMENOPAUSE; PULMONARY EMBOLISM; RISK FACTORS; VENOUS THROMBOEMBOLISM; VENOUS THROMBOSIS;

EID: 78650513899     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2010.241     Document Type: Article

References (30)

1. Scarabin, P.Y., Oger, E. & Plu-Bureau, G.; EStrogen and THromboEmbolism Risk Study Group. Diferential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk. Lancet 362, 428-432 (2003).
2. Straczek, C. et al.; Estrogen and Thromboembolism Risk (ESTHER) Study Group. Prothrombotic mutations, Hormone therapy, And venous thromboembolism among postmenopausal women: impact of the route of estrogen administration. Circulation 112, 3495-3500 (2005).
3. Canonico, M. et al.; Estrogen and Thromboembolism Risk (ESTHER) Study Group. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation 115, 840-845 (2007).
4. Canonico, M., Plu-Bureau, G., Lowe, G.D. & Scarabin, P.Y. Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: systematic review and meta-analysis. BMJ 336, 1227-1231 (2008).
5. Canonico, M. et al. Postmenopausal hormone therapy and risk of idiopathic venous thromboembolism: results from the E3N cohort study. Arterioscler. Thromb. Vasc. Biol. 30, 340-345 (2010).
6. De Lignieres, B. et al. Biological efects of estradiol-17 beta in postmenopausal women: oral versus percutaneous administration. J. Clin. Endocrinol. Metab. 62, 536-541 (1986).
7. Oger, E. et al.; SaRaH Investigators. Diferential efects of oral and transdermal estrogen/progesterone regimens on sensitivity to activated protein C among postmenopausal women: a randomized trial. Arterioscler. Thromb. Vasc. Biol. 23, 1671-1676 (2003).
8. Caine, Y.G. et al. Coagulation activation following estrogen administration to postmenopausal women. Thromb. Haemost. 68, 392-395 (1992).
9. Vehkavaara, S. et al. Efects of oral and transdermal estrogen replacement therapy on markers of coagulation, Fbrinolysis, Infammation and serum lipids and lipoproteins in postmenopausal women. Thromb. Haemost. 85, 619-625 (2001).
10. Canonico, M. et al.; Estrogen and Thromboembolism Risk (ESTHER) Study Group. Synergism between oral estrogen therapy and cytochrome P450 3a5*1 allele on the risk of venous thromboembolism among postmenopausal women. J. Clin. Endocrinol. Metab. 93, 3082-3087 (2008).
11. Thimmulappa, R.K., Mai, K.H., Srisuma, S., Kensler, T.W., Yamamoto, M. & Biswal, S. Identifcation of Nrf2-regulated genes induced by the chemopreventive agent sulforaphane by oligonucleotide microarray. Cancer Res. 62, 5196-5203 (2002).
12. Marzec, J.M. et al. Functional polymorphisms in the transcription factor NRF2 in humans increase the risk of acute lung injury. FASEB J. 21, 2237-2246 (2007).
13. Fukushima-Uesaka, H. et al. Genetic variations and haplotype structures of transcriptional factor Nrf2 and its cytosolic reservoir protein Keap1 in japanese. Drug Metab. Pharmacokinet. 22, 212-219 (2007).
14. Kobayashi, A. et al. Oxidative and electrophilic stresses activate Nrf2 through inhibition of ubiquitination activity of Keap1. Mol. Cell. Biol. 26, 221-229 (2006).
15. Venugopal, R. & jaiswal, A.K. Nrf1 and Nrf2 positively and c-Fos and Fra1 negatively regulate the human antioxidant response element-mediated expression of NaD(P)H:quinone oxidoreductase1 gene. Proc. Natl. Acad. Sci. USA 93, 14960-14965 (1996).
16. Cho, H.Y., Reddy, S.P., Debiase, A., Yamamoto, M. & Kleeberger, S.R. Gene expression profling of NRF2-mediated protection against oxidative injury. Free Radic. Biol. Med. 38, 325-343 (2005). (Pubitemid 40081112)
17. Ramos-Gomez, M. et al. Sensitivity to carcinogenesis is increased and chemoprotective efcacy of enzyme inducers is lost in nrf2 transcription factor-defcient mice. Proc. Natl. Acad. Sci. USA 98, 3410-3415 (2001).
18. Chan, K., Han, X.D. & Kan, Y.W. An important function of Nrf2 in combating oxidative stress: detoxifcation of acetaminophen. Proc. Natl. Acad. Sci. USA 98, 4611-4616 (2001).
19. Rangasamy, T. et al. Disruption of Nrf2 enhances susceptibility to severe airway infammation and asthma in mice. J. Exp. Med. 202, 47-59 (2005).
20. Ma, Q., Battelli, L. & Hubbs, A.F. Multiorgan autoimmune infammation, Enhanced lymphoproliferation, And impaired homeostasis of reactive oxygen species in mice lacking the antioxidant-activated transcription factor Nrf2. Am. J. Pathol. 168, 1960-1974 (2006).
21. Dai, G., Vaughn, S., Zhang, Y., Wang, E.T., Garcia-Cardena, G. & Gimbrone, M.A. jr. Biomechanical forces in atherosclerosis-resistant vascular regions regulate endothelial redox balance via phosphoinositol 3-kinase/akt-dependent activation of Nrf2. Circ. Res. 101, 723-733 (2007).
22. Rushmore, T.H., Morton, M.R. & Pickett, C.B. The antioxidant responsive element. Activation by oxidative stress and identifcation of the DNa consensus sequence required for functional activity. J. Biol. Chem. 266, 11632-11639 (1991).
23. Nioi, P., McMahon, M., Itoh, K., Yamamoto, M. & Hayes, J.D. Identifcation of a novel Nrf2-regulated antioxidant response element (aRE) in the mouse NaD(P)H:quinone oxidoreductase 1 gene: reassessment of the aRE consensus sequence. Biochem. J. 374, 337-348 (2003).
24. Raftogianis, R., Creveling, C., Weinshilboum, R. & Weisz, J. Estrogen metabolism by conjugation. J. Natl. Cancer Inst. Monographs 113-124 (2000).
25. Sonnet, E., Lacut, K., Roudaut, N., Mottier, D., Kerlan, V. & Oger, E. Efects of the route of oestrogen administration on IGF-1 and IGFBP-3 in healthy Postmenopausal women: results from a randomized placebo-controlled study. Clin. Endocrinol. (Oxf) 66, 626-631 (2007).
26. Park, S.A., Na, H.K., Kim, E.H., Cha, Y.N. & Surh, Y.J. 4-hydroxyestradiol induces anchorage-independent growth of human mammary epithelial cells via activation of IkappaB kinase: potential role of reactive oxygen species. Cancer Res. 69, 2416-2424 (2009).
27. Ansell, P.J. et al. In vitro and in vivo regulation of antioxidant response element-dependent gene expression by estrogens. Endocrinology 145, 311-317 (2004).
28. Ansell, P.J. et al. Repression of cancer protective genes by 17beta-estradiol: ligand-dependent interaction between human Nrf2 and estrogen receptor alpha. Mol. Cell. Endocrinol. 243, 27-34 (2005).
29. Ageno, W., Becattini, C., Brighton, T., Selby, R. & Kamphuisen, P.W. Cardiovascular risk factors and venous thromboembolism: a meta-analysis. Circulation 117, 93-102 (2008).
30. Roberts, C.K. & Sindhu, K.K. Oxidative stress and metabolic syndrome. Life Sci. 84, 705-712 (2009).